Tech Company Financing Transactions

MAP Pharmaceuticals Funding Round

MAP Pharmaceuticals closed a $50 million Series D investment round on 3/28/2007. Backers included D. E. Shaw Group, Bay City Capital and FirstMark Capital.

Transaction Overview

Company Name
MAP Pharmaceuticals
Announced On
3/28/2007
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series D
Investors

D. E. Shaw Group (Lead Investor)

Bay City Capital (Carl Goldfischer)

FirstMark Capital (Patrick Enright)

Perseus (Steven Elms)

Skyline Ventures (John Freund)

Proceeds Purpose
The funds will support Phase 3 trials of both pediatric asthma and migraine drug candidates.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
2400 Bayshore Parkway 200
Mountain View, CA 94043
USA
Phone
(650) 386-3100
Website
www.mappharma.com
Email Address
[email protected]
Overview
MAP is currently developing the proprietary Tempo Inhaler platform, a next-generation pressurized metered-dose inhaler (pMDI) that is designed for the pulmonary delivery of respiratory and systemic drug therapies.
Profile
MAP Pharmaceuticals LinkedIn Company Profile
Social Media
MAP Pharmaceuticals Company Twitter Account
Company News
MAP Pharmaceuticals News
Facebook
MAP Pharmaceuticals on Facebook
YouTube
MAP Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Timothy Nelson
  Timothy Nelson LinkedIn Profile  Timothy Nelson Twitter Account  Timothy Nelson News  Timothy Nelson on Facebook
Chief Financial Officer
Christopher Chai
  Christopher Chai LinkedIn Profile  Christopher Chai Twitter Account  Christopher Chai News  Christopher Chai on Facebook
Chief Scientific Officer
Thomas Armer
  Thomas Armer LinkedIn Profile  Thomas Armer Twitter Account  Thomas Armer News  Thomas Armer on Facebook
VP - Bus. Development
Anastasios Gianakakos
  Anastasios Gianakakos LinkedIn Profile  Anastasios Gianakakos Twitter Account  Anastasios Gianakakos News  Anastasios Gianakakos on Facebook
VP - General Counsel
Charlene Friedman
  Charlene Friedman LinkedIn Profile  Charlene Friedman Twitter Account  Charlene Friedman News  Charlene Friedman on Facebook
VP - General Counsel
Thomas McCracken
  Thomas McCracken LinkedIn Profile  Thomas McCracken Twitter Account  Thomas McCracken News  Thomas McCracken on Facebook
VP - Human Resources
Marco Rosa
  Marco Rosa LinkedIn Profile  Marco Rosa Twitter Account  Marco Rosa News  Marco Rosa on Facebook
VP - Manufacturing
Alan Petro
  Alan Petro LinkedIn Profile  Alan Petro Twitter Account  Alan Petro News  Alan Petro on Facebook
VP - Operations
Frederick Graff
  Frederick Graff LinkedIn Profile  Frederick Graff Twitter Account  Frederick Graff News  Frederick Graff on Facebook

 

 

Browse more venture capital transactions:

Prev: 3/28/2007: LitePoint venture capital transaction
Next: 3/28/2007: Ecrio venture capital transaction

 

Share this article

 

Where The Data Comes From

Our team works diligently to record all VC transactions involving tech companies. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.